Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Gross Margin (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Gross Margin for 16 consecutive years, with 77.63% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 27763.0% to 77.63% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 74.58% through Dec 2025, up 4600.0% year-over-year, with the annual reading at 74.45% for FY2025, 4587.0% up from the prior year.
  • Gross Margin hit 77.63% in Q4 2025 for Guided Therapeutics, up from 58.33% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q2 2021 to a low of 200.0% in Q4 2024.
  • Historically, Gross Margin has averaged 36.54% across 5 years, with a median of 67.09% in 2024.
  • Biggest five-year swings in Gross Margin: plummeted -27167bps in 2021 and later surged 27763bps in 2025.
  • Year by year, Gross Margin stood at 68.33% in 2021, then skyrocketed by 46bps to 100.0% in 2022, then plummeted by -50bps to 50.0% in 2023, then plummeted by -500bps to 200.0% in 2024, then surged by 139bps to 77.63% in 2025.
  • Business Quant data shows Gross Margin for GTHP at 77.63% in Q4 2025, 58.33% in Q3 2025, and 67.52% in Q2 2025.